Findings of Research Misconduct, 59626-59627 [2017-26961]
Download as PDF
59626
Federal Register / Vol. 82, No. 240 / Friday, December 15, 2017 / Notices
or other forms of information
technology to minimize the information
collection burden.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
[FR Doc. 2017–27013 Filed 12–14–17; 8:45 am]
ACTION:
BILLING CODE 4165–15–P
Findings of research
misconduct have been made on the part
of Matthew Endo, former graduate
student, Department of Chemistry,
University of Illinois at UrbanaChampaign. The questioned research
was supported by National Institute of
General Medical Sciences (NIGMS),
National Institutes of Health (NIH),
grant R01 GM080436. The
administrative actions, including three
(3) years of supervision, which are
implemented beginning on November
16, 2017, are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Matthew Endo, University of Illinois
at Urbana-Champaign: Based on the
Respondent’s admission, an assessment
conducted by University of Illinois at
Urbana-Champaign (UIUC), and analysis
conducted by ORI in its oversight
review, ORI found that Mr. Matthew
Endo, a former graduate student,
Department of Chemistry, UIUC,
engaged in research misconduct in
research supported by National Institute
of General Medical Sciences (NIGMS),
National Institutes of Health (NIH),
grant R01 GM080436.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, or recklessly causing false
data to be recorded, falsifying and/or
fabricating data and related images by
alteration and/or reuse and/or relabeling
of experimental data, and reporting
falsified and/or fabricated data in one
(1) manuscript subsequently submitted
for publication:
• ‘‘Amphotericin primarily kills human
cells by binding and extracting
cholesterol.’’ Submitted for
publication to the Proceedings of the
National Academy of Sciences
[withdrawn prior to peer review]
(hereafter referred to as ‘‘Manuscript
1’’)
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination Concerning a Petition
To Add a Class of Employees to the
Special Exposure Cohort
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice.
HHS gives notice of a
determination concerning a petition to
add a class of employees from the
Carborundum Company, in Niagara
Falls, New York, to the Special
Exposure Cohort (SEC) under the Energy
Employees Occupational Illness
Compensation Program Act of 2000
(EEOICPA).
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
National Institute for Occupational
Safety and Health (NIOSH), 1090
Tusculum Avenue, MS C–46,
Cincinnati, OH 45226–1938, Telephone
1–877–222–7570. Information requests
can also be submitted by email to
DCAS@CDC.GOV.
SUPPLEMENTARY INFORMATION:
Authority: [42 U.S.C.7384q].
sradovich on DSK3GMQ082PROD with NOTICES
On November 16, 2017, the Acting
Secretary of HHS determined that the
following class of employees does not
meet the statutory criteria for addition
to the SEC as authorized under
EEOICPA:
All employees who worked in any area of
the Carborundum Company facility on
Buffalo Avenue, Niagara Falls, New York,
from January 1, 1943, through December 31,
1976.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2017–27039 Filed 12–14–17; 8:45 am]
BILLING CODE 4163–19–P
VerDate Sep<11>2014
23:42 Dec 14, 2017
Jkt 244001
Specifically, ORI found that:
• In Manuscript 1, Respondent caused
falsified and/or fabricated results to
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
be recorded by knowingly requesting
biological testing of a mixture of
compounds that he falsely claimed to
be a single compound
• In Manuscript 1, Respondent falsified
and/or fabricated the results on page
S26 of the Supporting Information by
modifying the HPLC trace through
peak erasure to make the preparation
of C35deOAmB appear more pure
than in the actual results of
experimentation
• In Manuscript 1, Respondent falsified
and/or fabricated the results of
Surface Plasmon Resonance data on
page S7 of the Supporting Information
to make the error bars smaller than
the actual results of experimentation
• In Manuscript 1, Respondent falsified
and/or fabricated the results of a
WST08 Cell Proliferation Assay on
page S32 of the Supporting
Information by falsely claiming to run
the reaction in triplicate when it was
only performed in duplicate
• In correspondence with his advisor,
Respondent falsified and/or fabricated
the results of the preparation of
putative C2deoAmB where
Respondent modified and relabeled a
HPLC trace and relabeled an NMR
spectrum to falsely claim
characterization, purity, and
identification of sample that was sent
for biological assay
Mr. Endo entered into a Voluntary
Settlement Agreement and voluntarily
agreed for a period of three (3) years,
beginning on November 16, 2017:
(1) To have his research supervised;
Respondent agreed to ensure that prior
to the submission of an application for
PHS support for a research project on
which Respondent’s participation is
proposed and prior to Respondent’s
participation in any capacity on PHSsupported research, the institution
employing him must submit a plan for
supervision of Respondent’s duties to
ORI for approval; the plan for
supervision must be designed to ensure
the scientific integrity of Respondent’s
research contribution; Respondent
agreed that he will not participate in
any PHS-supported research until a plan
for supervision is submitted and
approved by ORI;
(2) that any institution employing him
must submit in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHS
supported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
E:\FR\FM\15DEN1.SGM
15DEN1
Federal Register / Vol. 82, No. 240 / Friday, December 15, 2017 / Notices
accurately reported in the application,
report, manuscript, or abstract;
(3) if no supervisory plan is provided
to ORI, to provide certification to ORI
on annual basis that he has not engaged
in, applied for, or had his name
included on any application, proposal,
or other request for PHS funds without
prior notification to ORI; and
(4) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
Kathryn M. Partin,
Director, Office of Research Integrity.
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination Concerning a Petition
To Add a Class of Employees to the
Special Exposure Cohort
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
AGENCY:
Notice.
HHS gives notice of a
determination concerning a petition to
add a class of employees from the Rocky
Flats Plant, in Golden, Colorado, to the
Special Exposure Cohort (SEC) under
the Energy Employees Occupational
Illness Compensation Program Act of
2000 (EEOICPA).
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
National Institute for Occupational
Safety and Health (NIOSH), 1090
Tusculum Avenue, MS C–46,
Cincinnati, OH 45226–1938, Telephone
1–877–222–7570. Information requests
can also be submitted by email to
DCAS@CDC.GOV.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
Authority: [42 U.S.C. 7384q].
On November 16, 2017, the Acting
Secretary of HHS determined that the
following class of employees does not
meet the statutory criteria for addition
to the SEC as authorized under
EEOICPA:
All employees of the Department of
Energy, its predecessor agencies, and their
contractors and subcontractors who worked
in any area of the Rocky Flats Plant in
VerDate Sep<11>2014
23:42 Dec 14, 2017
Jkt 244001
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2017–27040 Filed 12–14–17; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2017–26961 Filed 12–14–17; 8:45 am]
ACTION:
Golden, Colorado, from January 1, 1984,
through December 31, 2005.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Pre and Postnatal Neurologic
Disorders.
Date: December 19, 2017.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Suzan Nadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217B,
MSC 7846, Bethesda, MD 20892, 301–435–
1259, nadis@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 12, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–27108 Filed 12–14–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
59627
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
meeting of the Council of Councils.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov).
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4), and 552b(c)(6), Title 5
U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Council of Councils.
Open: January 26, 2018.
Time: 8:15 a.m. to 11:30 a.m.
Agenda: Call to Order and Introductions;
Announcements and Updates; Common
Fund 4D Nucleome Presentation; NIH
Update; Common Fund Concepts.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Closed: January 26, 2018.
Time: 12:15 p.m. to 1:30 p.m.
Agenda: Review of Grant Applications.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Open: January 26, 2018.
Time: 1:30 p.m. to 4:00 p.m.
Agenda: Tribal Health Research Office
Update and Input; Introduction of New
Working Group to Council of Councils;
Update & Input—Office of Research on
Women’s Health Strategic Plan; The ECHO
Program at Year One; Closing Remarks.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Franziska Grieder, D.V.M.,
Ph.D., Executive Secretary, Director, Office of
Research Infrastructure Programs, Division of
E:\FR\FM\15DEN1.SGM
15DEN1
Agencies
[Federal Register Volume 82, Number 240 (Friday, December 15, 2017)]
[Notices]
[Pages 59626-59627]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26961]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made on the part of
Matthew Endo, former graduate student, Department of Chemistry,
University of Illinois at Urbana-Champaign. The questioned research was
supported by National Institute of General Medical Sciences (NIGMS),
National Institutes of Health (NIH), grant R01 GM080436. The
administrative actions, including three (3) years of supervision, which
are implemented beginning on November 16, 2017, are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Matthew Endo, University of Illinois at Urbana-Champaign: Based on
the Respondent's admission, an assessment conducted by University of
Illinois at Urbana-Champaign (UIUC), and analysis conducted by ORI in
its oversight review, ORI found that Mr. Matthew Endo, a former
graduate student, Department of Chemistry, UIUC, engaged in research
misconduct in research supported by National Institute of General
Medical Sciences (NIGMS), National Institutes of Health (NIH), grant
R01 GM080436.
ORI found that Respondent engaged in research misconduct by
intentionally, knowingly, or recklessly causing false data to be
recorded, falsifying and/or fabricating data and related images by
alteration and/or reuse and/or relabeling of experimental data, and
reporting falsified and/or fabricated data in one (1) manuscript
subsequently submitted for publication:
``Amphotericin primarily kills human cells by binding and
extracting cholesterol.'' Submitted for publication to the Proceedings
of the National Academy of Sciences [withdrawn prior to peer review]
(hereafter referred to as ``Manuscript 1'')
Specifically, ORI found that:
In Manuscript 1, Respondent caused falsified and/or fabricated
results to be recorded by knowingly requesting biological testing of a
mixture of compounds that he falsely claimed to be a single compound
In Manuscript 1, Respondent falsified and/or fabricated the
results on page S26 of the Supporting Information by modifying the HPLC
trace through peak erasure to make the preparation of C35deOAmB appear
more pure than in the actual results of experimentation
In Manuscript 1, Respondent falsified and/or fabricated the
results of Surface Plasmon Resonance data on page S7 of the Supporting
Information to make the error bars smaller than the actual results of
experimentation
In Manuscript 1, Respondent falsified and/or fabricated the
results of a WST08 Cell Proliferation Assay on page S32 of the
Supporting Information by falsely claiming to run the reaction in
triplicate when it was only performed in duplicate
In correspondence with his advisor, Respondent falsified and/
or fabricated the results of the preparation of putative C2deoAmB where
Respondent modified and relabeled a HPLC trace and relabeled an NMR
spectrum to falsely claim characterization, purity, and identification
of sample that was sent for biological assay
Mr. Endo entered into a Voluntary Settlement Agreement and
voluntarily agreed for a period of three (3) years, beginning on
November 16, 2017:
(1) To have his research supervised; Respondent agreed to ensure
that prior to the submission of an application for PHS support for a
research project on which Respondent's participation is proposed and
prior to Respondent's participation in any capacity on PHS-supported
research, the institution employing him must submit a plan for
supervision of Respondent's duties to ORI for approval; the plan for
supervision must be designed to ensure the scientific integrity of
Respondent's research contribution; Respondent agreed that he will not
participate in any PHS-supported research until a plan for supervision
is submitted and approved by ORI;
(2) that any institution employing him must submit in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are
[[Page 59627]]
accurately reported in the application, report, manuscript, or
abstract;
(3) if no supervisory plan is provided to ORI, to provide
certification to ORI on annual basis that he has not engaged in,
applied for, or had his name included on any application, proposal, or
other request for PHS funds without prior notification to ORI; and
(4) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017-26961 Filed 12-14-17; 8:45 am]
BILLING CODE 4150-31-P